Basilea Pharmaceutica AG (BSLN)
SIX Swiss Exchange · Switzerland · prices in CHF · close of 23 Oct 2026
Key indicators
| Last close | CHF 68.50 |
|---|---|
| 52-week range | 44.70 – 70.50 |
| Return, 1 month / 3 months | −1.3% / +31.0% |
| Return, 1 year / 3 years | +40.5% / +85.1% |
| Trend | Uptrend |
| RSI (14) | 56 |
| Volatility (1 year) | 28.3% |
| Worst drawdown (1 year) | -16.9% |
| Average daily value traded | 2.76M CHF |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Basilea Pharmaceutica is a Swiss biopharmaceutical company based in Basel that develops and commercialises medicines for serious infections and cancer. Its products include antifungal and antibiotic treatments used in hospitals, along with cancer therapies developed for specialty care. The company works with partners to make these medicines available in markets around the world, and its customers are mainly hospitals, clinicians and healthcare systems that treat patients with difficult-to-treat conditions.
On this site Basilea Pharmaceutica AG appears as a stock on the SIX Swiss Exchange (Switzerland), code BSLN, with prices in Swiss francs (CHF). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Basilea Pharmaceutica AG (BSLN) trades on the SIX Swiss Exchange in Switzerland. It last closed at CHF 68.50 on 23 October 2026.
Its price-based Market X-Ray is 77 out of 100 (a strong price profile), ranking 9 of 226 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 40.5% and over the last three months it rose 31.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on SIX Swiss Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 89 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 21.3% | ||
| From 52-week high | -2.0% | ||
| Momentum | 87 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 31.0% | ||
| 6-month return | 27.1% | ||
| 12-month return, skipping the last month | 42.4% | ||
| Stability (higher is calmer) | 65 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 28.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -16.9% | ||
| Liquidity | 59 · Fair | Moderate trading activity. | |
| Average daily value traded | 2.76M CHF | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +4.4% |
|---|---|
| 1 month | −1.3% |
| 3 months | +31.0% |
| 6 months | +27.1% |
| 1 year | +40.5% |
| 3 years | +85.1% |
| 5 years | +59.8% |
Signals
| 50-day / 200-day average | 65.99 / 56.48 |
|---|---|
| Golden / death cross (60 days) | Golden, 46 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.96 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on SIX Swiss Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.